SacubitrilValsartanstive Heart Failure: Cardiogenic Shock
Joint Authors
Source
Issue
Vol. 2018, Issue 2018 (31 Dec. 2018), pp.1-3, 3 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2018-05-15
Country of Publication
Egypt
No. of Pages
3
Main Subjects
Abstract EN
Sacubitril/valsartan is a combination drug described as a new class of dual-acting angiotensin receptor-neprilysin inhibitor (ARNi) for heart failure.
We present a case of a patient with NYHA class IV systolic heart failure who was refractory to all other classes of heart failure medications and was started on this new medication.
On sacubitril/valsartan, he developed cardiogenic shock.
This led us to reevaluate the use and risks of this medication in the class IV heart failure population.
American Psychological Association (APA)
Rawal, H. A.& Kocheril, A. G.. 2018. SacubitrilValsartanstive Heart Failure: Cardiogenic Shock. Case Reports in Cardiology،Vol. 2018, no. 2018, pp.1-3.
https://search.emarefa.net/detail/BIM-1141321
Modern Language Association (MLA)
Rawal, H. A.& Kocheril, A. G.. SacubitrilValsartanstive Heart Failure: Cardiogenic Shock. Case Reports in Cardiology No. 2018 (2018), pp.1-3.
https://search.emarefa.net/detail/BIM-1141321
American Medical Association (AMA)
Rawal, H. A.& Kocheril, A. G.. SacubitrilValsartanstive Heart Failure: Cardiogenic Shock. Case Reports in Cardiology. 2018. Vol. 2018, no. 2018, pp.1-3.
https://search.emarefa.net/detail/BIM-1141321
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1141321
